4-chloro-5-propyl-pyrrolo[3,2-d]pyrimidine | 871024-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 4-chloro-5-propyl-pyrrolo[3,2-d]pyrimidine
• 英文别名: 4-chloro-5-propyl-5H-pyrrolo[3,2-d]pyrimidine；4-chloro-5-propylpyrrolo[3,2-d]pyrimidine
• CAS: 871024-44-1
• 化学式: C₉H₁₀ClN₃
• 分子量: 195.651
• InChiKey: OGXITDUIRXVDGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-5-propyl-pyrrolo[3,2-d]pyrimidine 、 3-氯-4-(3-氟苄氧基)苯胺 在 乙酸乙酯 、 Brine 、 magnesium sulfate 、 异丙醚 、 氯仿 、 resultant precipitate 作用下， 以 N-甲基吡咯烷酮 、 碳酸氢钠 为溶剂， 反应 2.0h， 以to give the title compound (96 mg) as a pale-purple powder的产率得到N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-propyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine
  参考文献：
  名称：

  Fused heterocyclic compound

  摘要：

  本发明涉及一种由以下公式表示的化合物：其中W为C（R1）或N，每个A为可选取代的芳基或杂环基，X1为—NR3—Y1—、—O—、—S—、—SO—、—SO2—或—CHR3—，其中R3为氢原子或可选取代的脂肪烃基，或R3可选择与A结合形成可选取代的环状结构，R1为氢原子或通过碳原子、氮原子或氧原子键合的可选取代基，R2为氢原子或通过碳原子或硫原子键合的可选取代基，或R1和R2，或R2和R3可选择结合形成可选取代的环状结构，或其盐，并且包含该化合物或其前药的酪氨酸激酶抑制剂或癌症预防或治疗剂。

  公开号：

  US07507740B2
• 作为产物：
  描述：

  溴丙烷 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.25h， 生成 4-chloro-5-propyl-pyrrolo[3,2-d]pyrimidine
  参考文献：
  名称：

  FUSED HETEROCYCLIC COMPOUND

  摘要：

  公开号：

  EP1752457B1

文献信息

• Fused Heterocyclic Compound
  申请人：Ishikawa Tomoyasu

  公开号：US20070244132A1

  公开（公告）日：2007-10-18

  The present invention relates to a compound represented by the formula: wherein W is C(R 1 ) or N, each A is an optionally substituted aryl group or a heteroaryl group, X 1 is —NR 3 —Y 1 —, —O—, —S—, —SO—, —SO 2 — or —CHR 3 — wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 is optionally bonded to A to form an optionally substituted ring structure, R 1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R 2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R 1 and R 2 , or R 2 and R 3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.

  本发明涉及一种化合物，其表示式为：其中W是C（R1）或N，每个A是可选取代的芳基或杂环基，X1是—NR3—Y1—、—O—、—S—、—SO—、—SO2—或—CHR3—，其中R3是氢原子或可选取代的脂肪烃基，或者R3与A可选地结合形成可选取代的环状结构，R1是氢原子或通过碳原子、氮原子或氧原子键合的可选取代基团，R2是氢原子或通过碳原子或硫原子键合的可选取代基团，或者R1和R2，或者R2和R3可选地键合形成可选取代的环状结构，或其盐，以及含有该化合物或其前药的酪氨酸激酶抑制剂或预防或治疗癌症的药物。
• Fused heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07507740B2

  公开（公告）日：2009-03-24

  The present invention relates to a compound represented by the formula: wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an optionally substituted ring structure, R1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.

  本发明涉及一种由以下公式表示的化合物：其中W为C（R1）或N，每个A为可选取代的芳基或杂环基，X1为—NR3—Y1—、—O—、—S—、—SO—、—SO2—或—CHR3—，其中R3为氢原子或可选取代的脂肪烃基，或R3可选择与A结合形成可选取代的环状结构，R1为氢原子或通过碳原子、氮原子或氧原子键合的可选取代基，R2为氢原子或通过碳原子或硫原子键合的可选取代基，或R1和R2，或R2和R3可选择结合形成可选取代的环状结构，或其盐，并且包含该化合物或其前药的酪氨酸激酶抑制剂或癌症预防或治疗剂。
• Pyrropyrimidine compounds as MNKs inhibitors
  申请人：LIFEARC

  公开号：US10604524B2

  公开（公告）日：2020-03-31

  The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: R1 is selected from H and CO—NR8R9, wherein R8 and R9 are each independently selected from H, alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted by one or more R12 groups, and said heterocycloalkyl is optionally substituted by R10 or R12; or R8 and R9 are linked, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted by one or more groups select from R10 and (CH2)mR12; R2 is selected from H and alkyl, wherein said alkyl group is optionally substituted by one or more R12 groups; R3 is selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may be optionally substituted by halo, OH or alkoxy; Z1, Z2, Z3 and Z4 are all C; R4, R5, R6 and R7 are each independently selected from H, alkyl, CN, NO2, OH, alkoxy, NHCO-alkyl, halo and haloalkyl; or Z1, Z3 and Z4 are all C, Z2 is N, R5 is absent and R4, R6 and R7 are as defined above; or Z1, Z3 and Z4 are all C, Z1 is N, R4 is absent and R5, R6 and R7 are as defined above; each R10 and R11 is independently alkyl; each R12 is independently selected from CO2R10, COOH, OH, alkoxy, haloalkyl, NH2, NHR10, NR10R11, heteroaryl and heterocycloalkyl; R13 is H or halo. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.

  本发明涉及式 I 的化合物或其药学上可接受的盐或酯，其中：R1选自H和CO-NR8R9，其中R8和R9各自独立地选自H、烷基、环烷基和单环或双环杂环烷基，其中所述烷基任选被一个或多个R12基团取代，所述杂环烷基任选被R10或R12取代；或 R8 和 R9 与所连接的氮相连，形成杂环烷基，该杂环烷基可选择含有一个或多个额外的杂原子，并可选择被一个或多个选自 R10 和 (CH2)mR12 的基团取代； R2 选自 H 和烷基，其中所述烷基可选择被一个或多个 R12 基团取代；R3选自烷基、环烷基和杂环烷基，其中每个环烷基可任选被卤代、OH或烷氧基取代；Z1、Z2、Z3和Z4均为C；R4、R5、R6和R7各自独立选自H、烷基、CN、NO2、OH、烷氧基、NHCO-烷基、卤代和卤代烷基；或Z1、Z3和Z4均为C，Z2为N，R5不存在，R4、R6和R7如上定义；或 Z1、Z3 和 Z4 均为 C，Z1 为 N，R4 不存在，R5、R6 和 R7 如上所定义；每个 R10 和 R11 独立为烷基；每个 R12 独立选自 CO2R10、COOH、OH、烷氧基、卤代烷基、NH2、NHR10、NR10R11、杂芳基和杂环烷基；R13 为 H 或卤代。进一步的方面涉及所述化合物的药物组合物和治疗用途，用于治疗细胞生长、增殖和/或存活失控的疾病、不适当的细胞免疫反应、不适当的细胞炎症反应或神经退行性疾病，优选牛磺酸病，更优选阿尔茨海默病。
• PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS
  申请人：LifeArc

  公开号：EP3377494B1

  公开（公告）日：2021-03-03
• Pyrropyrimidine Compounds As MNKS Inhibitors
  申请人：LIFEARC

  公开号：US20180346469A1

  公开（公告）日：2018-12-06

  The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: R 1 is selected from H and CO—NR 8 R 9 , wherein R 8 and R 9 are each independently selected from H, alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted by one or more R 12 groups, and said heterocycloalkyl is optionally substituted by R 10 or R 12 ; or R 8 and R 9 are linked, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted by one or more groups select from R 10 and (CH 2 ) m R 12 ; R 2 is selected from H and alkyl, wherein said alkyl group is optionally substituted by one or more R 12 groups; R 3 is selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may be optionally substituted by halo, OH or alkoxy; Z 1 , Z 2 , Z 3 and Z 4 are all C; R 4 , R 5 , R 6 and R 7 are each independently selected from H, alkyl, CN, NO 2 ,OH, alkoxy, NHCO-alkyl, halo and haloalkyl; or Z 1 , Z 3 and Z 4 are all C, Z 2 is N, R 5 is absent and R 4 , R 6 and R 7 are as defined above; or Z 1 , Z 3 and Z 4 are all C, Z 1 is N, R 4 is absent and R 5 , R 6 and R 7 are as defmed above; each R 10 and R11 is independently alkyl; each R 12 is independently selected from CO 2 R 10 , COOH, OH, alkoxy, haloalkyl, NH 2 , NHR 10 , NR 10 R 11 , heteroaryl and heterocycloalkyl; R 13 is H or halo. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.